Trials / Completed
CompletedNCT00197080
Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome
A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients With Restless Legs Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 380 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of ropinirole XR in the treatment of adults with Restless Legs Syndrome (RLS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ropinirole Extended Release (XR) |
Timeline
- Start date
- 2005-06-01
- Completion
- 2006-01-01
- First posted
- 2005-09-20
- Last updated
- 2016-09-23
Locations
70 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00197080. Inclusion in this directory is not an endorsement.